Basel, 15 September 2017 TECENTRIQ GO29695 (NCT02431208) and BO29562 (NCT02631577) partial clinical hold reactive statement Roche (SIX: RO, ROG; OTCQX: RHHBY): Based on emerging safety data from clinical trials evaluating pembrolizumab in combination with either lenalidomide or pomalidomide in multiple myeloma, the FDA has requested that a Phase Ib and a Phase Ib/II TECENTRIQ study... Read more
Four prominent surgeons and Leica Microsystems President Markus Lusser discussed the many ways Leica Microsystems is pushing the boundaries of visualization in the operating environment by integrating digital technologies directly into the surgical microscope. Seenu M. Hariprasad, MDShui-Chin Lee Professor of Ophthalmology and Visual ScienceChief, Vitreoretinal ServiceThe University of Chicago Medicine,... Read more
WAUKESHA, WI – September 5, 2017 – GE Healthcare announced today FDA 510(k) clearance of an industry-first, patient-assisted mammography device that literally puts women in control of their mammograms. Senographe Pristina Dueta is an innovative remote control that allows women to manage their own compression during the exam performed on the company’s new mammography system,... Read more
Download PDF Read more
Thermo Fisher Scientific to Present at the Morgan Stanley Global Healthcare Conference on September 11, 2017 WALTHAM, Mass., Sept. 5, 2017 /PRNewswire/ — Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, president and chief executive officer, will present at the Morgan Stanley Global Healthcare Conference on Monday,... Read more
Polarized light microscopes have been used in classical earth science studies for the last 100 years. Since then a lot of progress has been made to increase the user friendliness, ergonomy, and optical performance of such microscopes. Still, one thing has not changed: Classical polarized light (compound) microscopes can only be used for prepared samples,... Read more
Basel, 30 August 2017 FDA approves Roche’s Actemra/RoActemra (tocilizumab) for the treatment of CAR T cell-induced cytokine release syndrome Actemra/RoActemra is the first FDA-approved treatment for severe or life-threatening cytokine release syndrome induced by CAR T cell therapy CAR T cell therapy is an immunotherapy designed for the treatment of certain cancers This is the... Read more
Basel, 30 August 2017 FDA approves Roche’s Actemra/RoActemra (tocilizumab) for the treatment of CAR T cell-induced cytokine release syndrome Actemra/RoActemra is the first FDA-approved treatment for severe or life-threatening cytokine release syndrome induced by CAR T cell therapy CAR T cell therapy is an immunotherapy designed for the treatment of certain cancers This is the... Read more
August 30, 2017 Nikon Corporation is pleased to announce the “JEOL-Nikon CLEM Solution Center”, a collaborative project between Nikon and JEOL Ltd., will be established on September 1, 2017. The center will be opened in the R & D Building of JEOL to provide experience in and collect and deliver technical information on cutting-edge CLEM*... Read more
Since the spring of 2016, the U.S. Food and Drug Administration (FDA), the British Medicines and Healthcare products Regulatory Agency (MHRA), and other regulatory agencies have strengthened the monitoring of quality assurance at pharmaceutical companies. Companies must now show that nothing improper has been done when using analytical instruments. In addition, in graphs showing data... Read more